@article{oai:niigata-u.repo.nii.ac.jp:00020166,
 author = {中島, 喜章 and 畠山, 忍 and 鈴木, 栄一 and 永井, 明彦 and 来生, 哲 and 荒川, 正昭 and 俵谷, 幸蔵 and 原口, 通比古},
 issue = {5},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {May},
 note = {Twenty patients with small cell lung cancer (SCLC), 11 limited disease (LD) and 9 had extensive disease (ED), were treated with a combination chemotherapy consisting of ADM (40mg/m^2, i.v., day 1), VCR (1mg/m^2, i.v., day 1), ETP (60mg/m^2, i.v., day 1～5) and CPA (600mg/m^2, i.v., day 1) (AVEC therapy) at 4week intervals. The overall response rate and the complete response (CR) rate were 100% (11/11) and 36% (4/11) in LD cases, and 78% (7/9) and 0% (0/9) in ED cases, respectively. The median response duration were 9 months in LD cases and 2 months in ED cases. The median survival time of LD, ED and all cases were 13, 9 and 13 months, respectively. The over 3 years survival rate was 20% (4/20). The major toxicity was myelosupression, although it was well tolerated. These results suggest that the AVEC therapy is effective for SCLC.},
 pages = {444--450},
 title = {肺小細胞癌に対するAdriamycin, Vincristine, Etoposide, Cyclophosphamide (AVEC)併用療法},
 volume = {107},
 year = {1993}
}